Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05685173 · ClinicalTrials.gov registry record · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
A Phase 1 study of B-cell Non-Hodgkins Lymphoma (B-NHL), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 20
- Study locations
NCT05685173 is a Phase 1 study of B-cell Non-Hodgkins Lymphoma (B-NHL) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 91 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT05685173, a Phase 1 study of B-cell Non-Hodgkins Lymphoma (B-NHL), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab (called "study drugs"). The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects) * To find out how well the study drugs work against relapsed or refractory aggressive B-cell non-Hodgkin lymphomas (B-NHLs)
Conditions Studied
Interventions
- DRUG Odronextamab
- DRUG REGN5837
Study Locations (20)
California
- City of Hope - Duarte
- University of California Los Angeles (UCLA) Medical Center - Santa Monica
Massachusetts
- Massachusetts General Hospital - Boston
- Harvard Medical School - Beth Israel Deaconess Medical Center - Boston
New York
- NYU Langone Health Perlmutter Cancer Center - New York
- Icahn School of Medicine at Mount Sinai - New York
Kentucky
- Norton Cancer Institute - Louisville
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Texas
- UT Southwestern - Dallas
Nouvelle-Aquitaine
- CHU de Bordeaux - Talence
Paris
- Hopital Saint Louis - Paris
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2023-04-12 |
| Est. Completion | 2029-05-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05685173
The ClinicalTrials.gov registry entry for NCT05685173 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with B-cell Non-Hodgkins Lymphoma (B-NHL) appearing as the primary indexed condition, and to 2 interventions - of which Odronextamab is the first listed.
NCT05685173 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05685173 about?
NCT05685173 is a clinical study titled "A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas". The study is researching an experimental drug called REGN5837 in combination with another experimental drug, odronextamab (called "study drugs"). The aim of the study is to see how safe and tolerable the study drugs are, and to define the recommended dose for phase 2. The study is looking at sever...
What is the current status of trial NCT05685173?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2023-04-12. Estimated completion is 2029-05-16.
What conditions does trial NCT05685173 study?
This clinical trial studies the following conditions: B-cell Non-Hodgkins Lymphoma (B-NHL).
What interventions are being tested in trial NCT05685173?
The interventions under investigation include: Odronextamab (DRUG), REGN5837 (DRUG).
Who is sponsoring clinical trial NCT05685173?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05685173 being conducted?
This trial has 20 study locations across California, Kentucky, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.